Press release
Lipodystrophy Market to Show Substantial Growth During the Forecast Period | CombiGene, Galmed, Cell Praxis, Regeneron, Amryt Pharma, Zydus Cadila
Lipodystrophy Market
As per DelveInsight, the Lipodystrophy market dynamics are anticipated to change in the coming years owing to the rise in healthcare spending worldwide and the expected launch of emerging therapies.Currently, some of the key companies, such as Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others, are involved in drug development for Lipodystrophy. The emerging therapies for the treatment of Lipodystrophy include Volanesorsen, REGN4461, Empagliflozin, and others. Approval of these therapies will provide new and different treatment options to the patients and will hence drive the market.
DelveInsight's "Lipodystrophy Market Insights, Epidemiology, and Market Forecast 2032 [https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lipodystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Lipodystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Lipodystrophy Overview
Lipodystrophy is characterized by either a complete or partial loss of adipose tissue (lipoatrophy), which may occur alongside abnormal accumulation of adipose tissue (lipohypertrophy) in other body areas. This condition leads to various metabolic complications, highlighting the role of adipose tissue as a crucial endocrine organ. The amount and distribution of adipose tissue significantly impact metabolic health.
Lipodystrophy can be either inherited or acquired, with inherited forms being extremely rare. In patients with lipodystrophy, levels of circulating hormones secreted by adipose tissue, such as leptin and adiponectin, are often significantly reduced.
Recent advancements in understanding the disease mechanisms have led to new diagnostic and therapeutic strategies for lipodystrophy. Ongoing research and development are expected to introduce innovative therapies that address current unmet needs and enhance treatment options for the condition.
Lipodystrophy Market Key Facts [https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
In 2021, the US had the largest Lipodystrophy market size of ~USD 77 million among the 7MM countries.
Among the EU4 countries, France had the highest market size for Lipodystrophy in 2021, i.e., ~USD 26 million.
The lowest market size among EU4 countries was estimated in Italy, with ~USD 9 million in 2021.
The market size of Lipodystrophy in the UK was observed to be ~USD 8 million in 2021.
In 2021, the total incident cases of Lipodystrophy in the US were ~1,050 cases.
EU4 and the UK, in 2021, accounted for ~1,850 cases of Lipodystrophy, which are anticipated to increase by the year 2032.
Among the EU4 countries, the highest number of cases of Lipodystrophy was found in France, i.e., ~760 cases in the year 2021.
Lipodystrophy Market [https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Lipodystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Lipodystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Lipodystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Lipodystrophy Epidemiology, Segmented as -
Total Cases of Lipodystrophy in the 7MM [2019-2032]
Subtype-specific Cases of Lipodystrophy in the 7MM [2019-2032]
Gender-specific Cases of Lipodystrophy in the 7MM [2019-2032]
Lipodystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Lipodystrophy market or expected to be launched during the study period. The analysis covers the Lipodystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Lipodystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Lipodystrophy Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/lipodystrophy-market [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Lipodystrophy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Lipodystrophy. Regeneron Pharmaceuticals is leading the therapeutics market with its Lipodystrophy drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Lipodystrophy Therapeutics Market Include:
Amryt Pharma
Boehringer Ingelheim
Carmot Therapeutics
Cell Praxis
CombiGene
Galmed Pharmaceuticals
Ionis Pharmaceuticals
Lipigon Pharmaceuticals
Regeneron Pharmaceuticals
Thera Technologies
Zydus Cadila
And Many Others
Lipodystrophy Emerging and Marketed Drugs Covered in the Report Include:
Aramchol: Galmed Pharmaceuticals
CT-SCUP: Cell Praxis
EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies
Empagliflozin: Boehringer Ingelheim
Gene therapy: CombiGene
Mibavademab: Regeneron Pharmaceuticals
MYALEPT (metreleptin): Amryt Pharma
REGN4461: Regeneron Pharmaceuticals
Saroglitazar Magnesium: Zydus Cadila
WAYLIVRA (volanesorsen): Ionis Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/lipodystrophy-market [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Key Insights
2. Executive Summary
3. Lipodystrophy Competitive Intelligence Analysis
4. Lipodystrophy Market Overview at a Glance
5. Lipodystrophy Disease Background and Overview
6. Lipodystrophy Patient Journey
7. Lipodystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Lipodystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Lipodystrophy Unmet Needs
10. Key Endpoints of Lipodystrophy Treatment
11. Lipodystrophy Marketed Products
12. Lipodystrophy Emerging Drugs and Latest Therapeutic Advances
13. Lipodystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Lipodystrophy Market Outlook (In US, EU5, and Japan)
16. Lipodystrophy Access and Reimbursement Overview
17. KOL Views on the Lipodystrophy Market
18. Lipodystrophy Market Drivers
19. Lipodystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lipodystrophy-market-to-show-substantial-growth-during-the-forecast-period-combigene-galmed-cell-praxis-regeneron-amryt-pharma-zydus-cadila]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Market to Show Substantial Growth During the Forecast Period | CombiGene, Galmed, Cell Praxis, Regeneron, Amryt Pharma, Zydus Cadila here
News-ID: 3624390 • Views: …
More Releases from ABNewswire
Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers …
Miami, FL - Avanti Rides introduces a new chapter in ride-hailing by combining passenger safety, driver empowerment, and seamless technology into a single app. Designed for the evolving needs of both drivers and riders, Avanti is delivering smarter bookings, stronger protection, and unmatched flexibility.
Built for Drivers Who Want More Than Just Rides
Avanti Rides recognizes that drivers are the foundation of the platform and offers a range of benefits focused on…
UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
Hey there, Atlanta business warriors! Have you ever felt that picking the perfect Managed IT Service is a bit like choosing the ultimate wingman for your company's tech needs? Trust me, it's not just a matter of finding someone who looks good on paper. With technology increasingly steering the ship of our businesses, selecting a reliable Managed IT Service is becoming as crucial as that morning cup of coffee we…
3D-Engineering: How 3D Scanning Services Are Revolutionizing Modern Engineering …
Imagine being able to capture every nook and cranny of an object down to the most intricate detail. Sounds magical, right? That's the power of 3D scanning services [https://3d-engineering.net/engineering-services/3d-laser-scanning-services/] in today's engineering projects. Across industries, from automotive and construction to aerospace and healthcare, 3D scanning is transforming how things are measured, mapped, and made. Whether you're designing a new building or manufacturing precision components, 3D scanning takes you from the…
SLCLawyer: How a Separation Agreement Can Help Couples Save Thousands in Legal F …
Image: https://www.abnewswire.com/upload/2025/10/7d762be2535d9a3c2274975ea0a87869.jpg
When John and Mary decided to separate after 12 years of marriage, they thought they could handle it on their own. Money was tight, emotions were high, and the internet offered dozens of free and cheap separation agreement templates. They downloaded one, filled in the blanks, and signed it at the kitchen table.
At first, it seemed like a practical solution. They avoided paying lawyers, saved a few hundred dollars,…
More Releases for Lipodystrophy
Lipodystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction
Lipodystrophy is a rare and complex metabolic disorder characterized by the abnormal distribution or complete absence of body fat. Patients may present with severe insulin resistance, hypertriglyceridemia, fatty liver disease, and heightened cardiovascular risks, in addition to visible physical changes. The psychological and quality-of-life burden is substantial, making effective treatment critical.
Historically, management relied on symptomatic control through insulin sensitizers, lipid-lowering drugs, and lifestyle interventions. The approval of metreleptin (a recombinant…
Lipodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Lipodystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Lipodystrophy Research. Learn more about our innovative pipeline…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
HIV Associated Lipodystrophy Syndrome Market 2017-2025 | TMR Research
Global HIV Associated Lipodystrophy Syndrome Market: Snapshot
HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus (HIV)-infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Patients have lipohypertrophy, an abnormal central fat accumulation or lipoatrophy, localized loss of fat tissue, or a mixed clinical presentations representing both. The complex morphological signs associated with lipodystrophy syndrome inhibits our understanding of the etiology…
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The…
HIV-associated Lipodystrophy Market Research Report 2017
Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities,…
